Compare Enbridge Inc (ENB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Sanofi SA — how do they compare? Enbridge Inc trades at $51.57 (market cap $112.62B), while Sanofi SA trades at $43.59 (market cap $104.30B). The key difference: Enbridge Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ENB | SNY | |
|---|---|---|
Market Cap | $112.62B | $104.30B |
Sector | Energy | Health |
52-Week High | $58.04 | $52.34 |
52-Week Low | $45.23 | $41.33 |
Enterprise Value | $196.53B | $124.19B |
Dividend Yield | 5.34% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.51, up 0.23% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend history with 31 consecutive years of increases. Revenue grew to $65.19B in 2025, though net income margin is expected to dip to 7.33% in 2026. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is mixed: robust infrastructure demand and a $41B project backlog support growth, but legal challenges and volatile energy markets pose risks. The stock offers a solid yield and consistent dividend growth, appealing for income investors, yet faces headwinds from regulatory scrutiny and debt levels nearing 49% of assets.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
